Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Betta Pharmaceuticals Co., Ltd.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed locally advanced/metastatic (stage IIIB/stage IV, using the American Joint Committee on Cancer \[AJCC\] 6th edition of tumor-node-metastasis \[TNM\] staging system) NSCLC patients
Progressed after at least one platinum-based chemotherapy regimen at entry
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
At least one measurable lesion by Response Evaluation Criteria in Solid Tumors version 1.0
Adequate hematologic and biochemical values
You may not be if
Patients with symptomatic brain metastases
Malignant tumor within the previous five years
Severe infection; congestive heart failure
Previous treatment with drugs targeting EGFR
History of interstitial lung disease
Clareo Health | Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
